-
ALS, stress response and Inflectis’ new drug.
A few years ago there was a phase II of Guanabenz in Italy. Guanabenz is a drug used to treat hypertension.
The results indicated that this drug was roughly as effective as AMX0035 from Amylyx.
Yet at the dose tested, this drug was unsafe on the long term so a new version was designed: Sephin 1.
This new drug will be tested in a few months in France and Italy in a new phase II trial.
https://alsnewstoday.com/news-posts/2022/03/31/inflectis-ifb-088-orphan-drug-status-fda-als-treatment/I guess the mecanism of this drug and of sodium phenylbutyrate is interesting as they both address the cellular stress even if an opposite way.
My understanding is that after the failure of Arimoclomol, and the two genetic therapies (SOD1 and C9orf72) of Biogen, research should study new paradigms. Cellular stress in ALS and other neurodegenerative diseases offers a clear mechanism of action when most proposed drugs fail to do so.
Sorry, there were no replies found.
Log in to reply.